🇺🇸 National Board Dental Examination / Integrated National Board Dental Examination (INBDE) · subject

National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management Syllabus

The Pharmacology and Pain/Anxiety Management syllabus for National Board Dental Examination / Integrated National Board Dental Examination (INBDE) in full: 4 chapters, 14 topics and 10 sub-topics, every one listed below, plus 50 Pharmacology and Pain/Anxiety Management flashcards with answers.

4Chapters
14Topics
10Sub-topics
50Flashcards

Pharmacology and Pain/Anxiety Management syllabus: all 4 chapters

Expand any chapter to see its topics and sub-topics.

  1. Pharmacologic Principles

    4 topics
    • Pharmacokinetics: absorption, distribution, metabolism, excretion
    • Pharmacodynamics and dose-response relationships
      • Agonists, antagonists, and receptor theory
      • Therapeutic index and toxicity
    • Drug interactions and adverse reactions
    • Autonomic nervous system pharmacology
  2. Local Anesthetics and Pain Control

    3 topics
    • Mechanism of action and chemistry of local anesthetics
      • Amides versus esters
      • Vasoconstrictor rationale and limits
    • Maximum recommended doses and toxicity management
    • Analgesics: NSAIDs, acetaminophen, and opioids
      • Multimodal analgesia for dental pain
      • Opioid stewardship and prescribing safety
  3. Antimicrobials and Therapeutic Agents

    4 topics
    • Antibiotics in dentistry and resistance
      • Spectrum and indications for common agents
      • Antibiotic prophylaxis guidelines
    • Antifungal and antiviral agents for oral disease
    • Anti-inflammatory and corticosteroid therapy
    • Hemostatic and fluoride therapeutic agents
  4. Sedation and Systemic Drug Considerations

    3 topics
    • Anxiolytics and minimal/moderate sedation pharmacology
      • Nitrous oxide-oxygen sedation
      • Benzodiazepines and monitoring
    • Cardiovascular and anticoagulant medications
    • Endocrine, psychiatric, and respiratory medication impacts on care

National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management flashcards — 50 questions with answers

  1. What are the four core pharmacokinetic processes that describe a drug's movement through the body (ADME)?

    Absorption (entry into the bloodstream), Distribution (movement to tissues), Metabolism (biotransformation, mainly hepatic), and Excretion (elimination, mainly renal).

  2. What is first-pass metabolism and which route avoids it?

    First-pass metabolism is hepatic breakdown of an orally absorbed drug via the portal vein before reaching systemic circulation, reducing bioavailability. IV, sublingual, rectal, and inhalational routes largely bypass it.

  3. Define bioavailability (F) and state its value for an intravenous drug.

    Bioavailability is the fraction of an administered dose reaching systemic circulation unchanged. For an IV drug, F = 1 (100%).

  4. What is the elimination half-life (t1/2), and roughly how many half-lives are needed to reach steady state or eliminate a drug?

    The time required for plasma drug concentration to fall by 50%. About 4-5 half-lives are needed to reach steady state or to essentially eliminate a drug (~94-97%).

  5. Which cytochrome P450 enzyme metabolizes the largest fraction of clinically used drugs, and where is it predominantly located?

    CYP3A4, located predominantly in the liver and intestinal wall.

  6. What is the difference between Phase I and Phase II hepatic metabolism reactions?

    Phase I reactions (oxidation, reduction, hydrolysis; mainly CYP450) introduce/expose functional groups. Phase II reactions (conjugation such as glucuronidation, sulfation, acetylation) attach polar groups to increase water solubility for excretion.

  7. How does the loading dose differ from the maintenance dose in calculation?

    Loading dose = (Vd x target concentration) / F; it rapidly achieves therapeutic level. Maintenance dose = (Clearance x target concentration x dosing interval) / F; it replaces eliminated drug to keep steady state.

  8. Define volume of distribution (Vd) and what a large Vd indicates.

    Vd = amount of drug in body / plasma concentration. A large Vd indicates extensive distribution into tissues (e.g., lipophilic drugs) rather than remaining in plasma.

  9. How does urine pH affect excretion of weak acids and weak bases (ion trapping)?

    Alkaline urine enhances excretion of weak acids (ionized, trapped) e.g., aspirin overdose treated with bicarbonate. Acidic urine enhances excretion of weak bases. Ionized drug is trapped in the tubule and excreted.

  10. What is the difference between drug efficacy and drug potency?

    Efficacy is the maximal effect a drug can produce (Emax). Potency is the amount of drug needed to produce a given effect (related to EC50/ED50); a more potent drug needs a lower dose.

  11. Define agonist, antagonist, and partial agonist.

    Agonist: binds and activates a receptor to produce a full response. Antagonist: binds but produces no response and blocks agonists. Partial agonist: binds and produces a submaximal response even at full occupancy.

  12. What is the therapeutic index (TI), and does a high or low TI indicate a safer drug?

    TI = TD50/ED50 (or LD50/ED50). A high TI indicates a wide safety margin (safer); a low TI (e.g., warfarin, digoxin, lithium) requires careful monitoring.

  13. Differentiate competitive from non-competitive antagonism in terms of dose-response curve effects.

    Competitive antagonists shift the agonist dose-response curve to the right (reduced potency) but Emax is unchanged and surmountable with more agonist. Non-competitive antagonists lower Emax (reduced efficacy) and cannot be overcome.

  14. What is the ED50 on a quantal dose-response curve?

    The dose at which 50% of the population shows the specified therapeutic response.

  15. Distinguish pharmacokinetic from pharmacodynamic drug interactions.

    Pharmacokinetic interactions alter a drug's absorption, distribution, metabolism, or excretion (changing its concentration). Pharmacodynamic interactions alter the drug's effect at the site of action (additive, synergistic, or antagonistic) without changing concentration.

  16. What is a CYP enzyme inducer vs inhibitor, and how does each affect plasma levels of a co-administered substrate?

    An inducer (e.g., rifampin, carbamazepine, phenytoin) increases enzyme activity, lowering substrate levels and effect. An inhibitor (e.g., erythromycin, ketoconazole, grapefruit juice) decreases activity, raising substrate levels and toxicity risk.

  17. What are the cholinergic (muscarinic) effects produced by parasympathetic stimulation relevant to dentistry?

    Increased salivation, lacrimation, sweating, bronchoconstriction, bradycardia, miosis, and increased GI motility (rest-and-digest, SLUDGE effects).

  18. Which adrenergic receptor mediates vasoconstriction, and which mediates increased heart rate?

    Alpha-1 receptors mediate vasoconstriction; beta-1 receptors mediate increased heart rate and contractility (beta-2 mediates bronchodilation and vasodilation in skeletal muscle).

  19. Why is epinephrine added to local anesthetics, and which receptor does it act on locally?

    Epinephrine causes local vasoconstriction via alpha-1 receptors, prolonging anesthetic duration, reducing systemic absorption/toxicity, and providing hemostasis.

  20. What is the chemical structure shared by local anesthetics, and what distinguishes the two classes?

    LAs have a lipophilic aromatic ring, an intermediate chain, and a hydrophilic amine. The intermediate linkage defines the class: esters (one 'i', e.g., procaine, benzocaine) vs amides (two 'i's, e.g., lidocaine, articaine).

Show the other 30 Pharmacology and Pain/Anxiety Management flashcards
  1. What is the mechanism of action of local anesthetics?

    They reversibly block voltage-gated sodium channels from the intracellular side, preventing sodium influx, depolarization, and propagation of the nerve action potential.

  2. Why do local anesthetics fail in infected (inflamed, acidic) tissue?

    Low pH increases the ionized (charged) form of the LA and decreases the uncharged base form that crosses the nerve membrane, so less drug penetrates to block sodium channels.

  3. How are amide vs ester local anesthetics metabolized?

    Amides are metabolized in the liver by CYP450 microsomal enzymes; esters are hydrolyzed in plasma by pseudocholinesterase, producing PABA (associated with allergic reactions).

  4. What is the maximum recommended dose of lidocaine with epinephrine, and the absolute mg cap for an adult?

    7 mg/kg with epinephrine (and 4.4 mg/kg plain), not to exceed an absolute maximum of about 500 mg with epinephrine in a healthy adult.

  5. A 2% lidocaine cartridge of 1.8 mL contains how many mg of lidocaine?

    2% = 20 mg/mL, so 20 x 1.8 = 36 mg of lidocaine per cartridge.

  6. What is the early sign of local anesthetic systemic toxicity (LAST) on the CNS, and how is severe LAST managed?

    Early CNS signs include circumoral numbness, tinnitus, dizziness, and lightheadedness, progressing to seizures then CNS depression. Severe LAST is treated with airway support and 20% IV lipid emulsion therapy.

  7. Which local anesthetic is associated with methemoglobinemia, and what is the treatment?

    Benzocaine (and prilocaine) can cause methemoglobinemia; treatment is IV methylene blue.

  8. What is the mechanism of action of NSAIDs?

    NSAIDs inhibit cyclooxygenase (COX-1 and COX-2), blocking conversion of arachidonic acid to prostaglandins, thereby reducing pain, inflammation, and fever.

  9. Why does aspirin pose a particular bleeding risk before dental surgery?

    Aspirin irreversibly acetylates COX-1 in platelets, inhibiting thromboxane A2 and platelet aggregation for the platelet's lifespan (~7-10 days), unlike reversible NSAIDs.

  10. How does acetaminophen differ from NSAIDs in action and key toxicity?

    Acetaminophen is analgesic and antipyretic but has minimal anti-inflammatory/antiplatelet effect and acts centrally. Its key toxicity is hepatotoxicity in overdose (max ~4 g/day in adults); antidote is N-acetylcysteine.

  11. What is the mechanism of action of opioid analgesics?

    Opioids agonize mu (and kappa/delta) opioid receptors in the CNS, inhibiting ascending pain pathways and altering pain perception; they also cause respiratory depression, sedation, constipation, and miosis.

  12. What is the antidote for opioid overdose and its mechanism?

    Naloxone, a competitive mu-opioid receptor antagonist that rapidly reverses respiratory depression and sedation (short-acting, may require redosing).

  13. What is the first-line antibiotic for most odontogenic infections, and the alternative for penicillin-allergic patients?

    Amoxicillin (or penicillin VK) is first-line. For penicillin-allergic patients, clindamycin (historically) or azithromycin/clarithromycin; current AHA guidance favors azithromycin/clarithromycin or doxycycline.

  14. What is the AHA recommended antibiotic prophylaxis regimen for infective endocarditis in at-risk patients before dental procedures?

    Amoxicillin 2 g orally (50 mg/kg children) 30-60 minutes before the procedure; clindamycin is no longer recommended for penicillin-allergic patients (use azithromycin/clarithromycin or doxycycline/cephalexin).

  15. How does bacterial resistance via beta-lactamase work, and how is it overcome in dentistry?

    Beta-lactamase enzymes hydrolyze the beta-lactam ring, inactivating penicillins. It is overcome by adding a beta-lactamase inhibitor like clavulanic acid (amoxicillin-clavulanate / Augmentin).

  16. Which antibiotic is most associated with Clostridioides difficile pseudomembranous colitis?

    Clindamycin, though most broad-spectrum antibiotics can cause it.

  17. What is the first-line topical antifungal for oral candidiasis, and a systemic alternative?

    Topical nystatin (suspension or pastilles) or clotrimazole troches; systemic alternative is fluconazole.

  18. What antiviral is used for recurrent herpes labialis/orolabial HSV, and what is its mechanism?

    Acyclovir (or valacyclovir/penciclovir); it is phosphorylated by viral thymidine kinase and inhibits viral DNA polymerase, terminating DNA chain elongation.

  19. What is the mechanism of corticosteroids' anti-inflammatory action?

    Corticosteroids inhibit phospholipase A2 (via lipocortin/annexin-1), blocking arachidonic acid release and thus both prostaglandin and leukotriene synthesis, plus broad immunosuppressive gene effects.

  20. Why must dental clinicians be aware of long-term systemic corticosteroid use, and what is the concern with abrupt stress?

    Chronic steroids suppress the HPA axis, risking adrenal crisis under surgical stress; supplemental ('stress dose') steroids may be considered, and abrupt cessation must be avoided to prevent adrenal insufficiency.

  21. What are common topical and systemic hemostatic agents used in dentistry?

    Topical: gelatin sponge (Gelfoam), oxidized cellulose (Surgicel), collagen, thrombin, and tranexamic acid mouthrinse. Systemic adjunct: aminocaproic/tranexamic acid (antifibrinolytics).

  22. What is the mechanism by which fluoride prevents caries and aids remineralization?

    Fluoride incorporates into enamel forming fluorapatite (more acid-resistant than hydroxyapatite), promotes remineralization, and inhibits bacterial enzymes (e.g., enolase) reducing acid production.

  23. What are the signs of acute fluoride toxicity and the probable toxic dose?

    Nausea, vomiting, abdominal pain, hypersalivation, and in severe cases cardiac arrhythmias/hypocalcemia. The probably toxic dose (PTD) is ~5 mg/kg; treat with milk/calcium and seek care; lethal dose ~32-64 mg/kg.

  24. What is the mechanism of action of benzodiazepines used for dental anxiolysis/sedation?

    They bind the GABA-A receptor benzodiazepine site and increase the frequency of chloride channel opening, enhancing GABA-mediated inhibition (sedation, anxiolysis, amnesia, muscle relaxation).

  25. What is the reversal agent for benzodiazepine oversedation?

    Flumazenil, a competitive benzodiazepine receptor antagonist (short-acting; monitor for resedation and seizure risk in dependent patients).

  26. What are the advantages of nitrous oxide-oxygen for minimal sedation in dentistry?

    Rapid onset and recovery, easy titration, analgesic and anxiolytic effects, minimal cardiovascular/respiratory depression, and quick reversal with 100% oxygen; minimum 30% oxygen must always be delivered.

  27. Why must epinephrine in local anesthetic be limited in patients with significant cardiovascular disease, and what is the cardiac dose limit?

    Exogenous epinephrine can raise heart rate and blood pressure and provoke arrhythmias. The cardiac patient limit is ~0.04 mg epinephrine (about 2 cartridges of 1:100,000).

  28. How do warfarin and the direct oral anticoagulants (DOACs) differ in mechanism, and what lab monitors warfarin?

    Warfarin inhibits vitamin K epoxide reductase (blocking factors II, VII, IX, X) and is monitored by INR (target ~2-3). DOACs directly inhibit factor Xa (apixaban, rivaroxaban) or thrombin (dabigatran) and need no routine monitoring.

  29. What dental adverse effect is associated with calcium channel blockers (e.g., nifedipine), phenytoin, and cyclosporine?

    Gingival hyperplasia/overgrowth.

  30. Which class of antidepressants poses a risk of hypertensive crisis with epinephrine or tyramine, and which antihypertensive interacts with NSAIDs?

    Nonselective MAO inhibitors (and tricyclic antidepressants potentiate sympathomimetics) raise hypertensive crisis risk. NSAIDs blunt the effect of ACE inhibitors and other antihypertensives and can raise blood pressure.

National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management FAQ

What is in the National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management syllabus?

National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management is split into 4 chapters: Pharmacologic Principles, Local Anesthetics and Pain Control, Antimicrobials and Therapeutic Agents and Sedation and Systemic Drug Considerations. Together they contain 14 topics and 10 sub-topics.

How many chapters are in National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management?

4 chapters, containing 14 topics and 10 sub-topics. The largest chapter is Pharmacologic Principles, with 4 topics.

Are there flashcards for National Board Dental Examination / Integrated National Board Dental Examination (INBDE) Pharmacology and Pain/Anxiety Management?

Yes — a 50-card Pharmacology and Pain/Anxiety Management deck, printed in full in the flashcards section of this page and available in the Examius app with spaced repetition. The free plan covers one exam of your choice, including its flashcards; Examius Pro, a one-time purchase, unlocks every other exam and deck.